Drug Profile
CGP 40774
Alternative Names: JT 3003Latest Information Update: 20 Mar 2002
Price :
$50
*
At a glance
- Originator Novartis
- Developer Jenner Biotherapies (CEASED)
- Class Antineoplastics
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Mucositis; Myelosuppression
Most Recent Events
- 20 Mar 2002 No development reported for cancer, myelosuppression or mucositis in the USA
- 30 Jul 1998 No-Development-Reported for Cancer in USA (PO)
- 30 Jul 1998 No-Development-Reported for Mucositis in USA (PO)